Good news and honorary awards

　　The main developer of the new anti-tumor immune compound therapy TTV

　　Academician Wang Zhenyi, the developer of TTV of Herun Group

　　Centennial academician Wang Zhenyi was awarded the "Medal of the Republic" On September 13, President Xi Jinping signed the Presidential Order. According to the decision of the Standing Committee of the National People's Congress on the 75th anniversary of the founding of the People's Republic of China, which was voted on by the 11th meeting of the Standing Committee of the 14th National People's Congress on the morning of the 13th, 15 people were awarded the National Medal and the National Honorary Title.

　　Among them, Wang Zhenyi, the former president of Shanghai Second Medical University (now Shanghai Jiaotong University School of Medicine), former director of Shanghai Institute of Hematology, lifelong professor of Ruijin Hospital, academician of the Chinese Academy of Engineering, and winner of the National Highest Science and Technology Award, was awarded the "Medal of the Republic".

　　Professor Wang Zhenyi is known as the "Father of Cancer-Induced Differentiation". The International Asteroid Center permanently named asteroid 43259 as "Wang Zhenyi Star".

　　What is tumor immunotherapy?

　　1. Tumor immunotherapy is a method of using the body's own immune system to treat tumors.

　　2. By restarting and maintaining the tumor-immune cycle.

　　3. Restore the body's normal anti-tumor immune response.

　　4. Control and eliminate tumors.

　　Various classification methods of immunotherapy

　　1. According to the impact on the body's immune function, it can be divided into immunoenhancement therapy and immunosuppression therapy.

　　2. According to the specificity of the treatment, it can be divided into specific immunotherapy and nonspecific immunotherapy.

　　3. According to the characteristics of the immune preparations, it can be divided into active immunotherapy and passive immunotherapy.

　　4. According to the preparations used for treatment, it can be divided into molecular therapy, cell therapy and immunomodulatory therapy.

　　Emphasis on "Inactivated and attenuated bacteria as vaccines belong to cell vaccines"

　　New anti-tumor compound immunotherapy

　　Tumor Therapeutic Vaccine， TTV

　　Continue and develop the great practice of Coley， the "father of cancer immunotherapy"， more than 100 years ago

　　Follow and practice the innovative anti-cancer concept of Academician Wang Zhenyi， the "father of cancer-induced differentiation".

　　Cancer "volunteers" test each other and write "real-world evidence" with the miracle of life

　　Origin of TTV research

　　1990's Mixed bacterial vaccine

　　mixed bacterial vaccine+adjuvant（biological，chemical）

　　TTV, the most advanced new anti-tumor combination therapy in China

　　1. Activate different types of immune mechanisms and immune cells.

　　2. Eliminate different types of cancer cells.

　　3. Produce additive or synergistic effects.

　　TTV anti-tumor combination therapy, also known as tumor therapy, is made from tumor cell-related antigens. After injection into the body, it can achieve the effect of activating the human immune system, help improve and enhance physical fitness, exert specific anti-tumor effects, prevent tumor diseases, and effectively reduce the incidence of cancer lesions.

　　TTV mechanism of action

　　Tumor immunity includes natural immunity and adaptive immunity. The mechanism of action of TTV is definitely related to promoting the body's immunity. TTV can:

　　Promote the secretion of endogenous interferon, IL-2, and TNF;

　　Enhance the phagocytic function of macrophages;

　　Promote lymphocyte transformation;

　　Increase the activity of NK cells;

　　Change T cell subsets;

　　Change the lectin receptors on the tumor cell membrane;

　　Morphologically increase the wet weight of the spleen;

　　Promote the proliferation of the spleen germinal center, etc.;

　　Clinical research tumor inhibition rate

　　From 1990 to 2008, 5 research institutions in Shanghai

　　Tumor models:

　　Liver, lung, bladder cancer, melanoma, sarcoma

　　Research results:

　　Inhibition rate>50%, up to 79%

　　From 1990 to early 2008, 12 researchers from 5 different institutions in Shanghai conducted research on more than 20 tumor animal models, including liver cancer, sarcoma, lung cancer, melanoma, and bladder cancer. A total of 29 formulations were tested, and the results showed that TTV has a significant and highly consistent anti-cancer effect, with an inhibition rate of more than 50% in almost all tumor models, and up to 79%. TTV is a complex of multiple bacterial therapies. The experimental results of the Shanghai Institute of Biochemistry and Cell Biology show that TTV is highly safe and non-toxic.

　　TTV recommended indications

　　After surgery, patients with a high probability of recurrence, who need to prevent recurrence;

　　Breast cancer, colorectal cancer, lung cancer, ovarian cancer, etc., who are expected to have a long survival period and are tumor survivors; consolidation treatment after conventional treatments such as surgery, chemotherapy and radiotherapy;

　　Patients with severe pain and a long expected survival period, who need to improve symptoms;

　　Tumor immunotherapy

　　Cancer is a highly complex disease, characterized by not only the overgrowth of malignant cells, but also changes in immune responses.

　　The suppression and reprogramming of the immune system play a key role in the occurrence and development of tumors.

　　The goal of immunotherapy is to reactivate anti-tumor immune cells and overcome the immune escape mechanism of tumors.

　　Currently effective treatments include curative cancer therapies, immune checkpoint blockade, bispecific T cell engagement and adaptive cell therapy.